CD19 and precursor B-cell acute lymphoblastic leukemia: For NUDT21-driven alternative polyadenylation of CD19 mRNA, genetic suppression of NUDT21 increases CD19 abundance via alternative polyadenylation control and re-sensitizes B-ALL/BLASTS to CD19 CAR-T or blinatumomab in preclinical models [15].